Clinical Trial Update: Senaparib in mCRPC Patients With Homologous Recombination Repair Gene Alterations After Docetaxel Treatment [Phase 2]

View source ↗

Summary

Phase 2 trial update on senaparib in metastatic castration-resistant prostate cancer patients with homologous recombination repair gene alterations after doceta…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer

Drugs mentioned

• Senaparib (senaparib)

Snippet

Sponsor: Impact Therapeutics, Inc. | Conditions: mCRPC | Phase 2 | Status: UNKNOWN